1. Dept. & Center for Biotechnology Research, Semnan University of Medical Sciences, Semnan, Iran. Students Research Committe, Semnan University of Medical Sciences, Semnan, Iran. 2. Dept. & Center for Biotechnology Research, Semnan University of Medical Sciences, Semnan, Iran.
Cancer immunotherapy is an exciting technique which stimulates the body to attack tumor cells. one aspect of this type of cancer treatment is the antibody-based therapies. conventional approaches of antibody immunotherapy have limitations such as high production and storage costs, and the requirement for repeated dosing due to short in vivo half-life. a novel potential strategy for antibody-based immunotherapy is synthetic mrna that encodes a therapeutic antibody. this review presents the latest developments of mrna technology in the field of antibody production for cancer immunotherapy, as well as discussing challenges and future prospects of this attractive alternative approach.
This is a review essay.
Mrna therapeutics hold promise to be a controllable and safe alternative to dna-based approaches, as well as simple and cost-effective alternative to recombinant antibody therapies. in vitro transcribed (ivt) mrna encoding antibody can direct in vivo expression of high levels of functional antibody. repeated intravenous administration of ivt mrna at a low dose has shown clear and strong anti-tumor effects. the serum half-life of mrna can be regulated by various modifications and delivery systems. the flexibility of mrna technology has shown by the expression of various antibodies and antibody formats. some antibody formats bear manufacturing challenges and short in vivo half-life, and mrna technology can circumvent these limitations.
Formulated mrnas can successfully produce efficient therapeutic antibodies in the host tissues and can act as a novel strategy for the development of cancer immunotherapy.